Aplastic Anemia and Eltrombopag

Choudhry VP*

Department of Hematology, All India Institute of Medical Science, India

Abstract

Aplastic anemia which was once considered as rare and invariably fatal disease. Over the years the understanding of its pathophysiology, its relationship with constitutional bone marrow failure syndrome and evolution to myelodysplastic syndrome and leukemia has improved. Evolution of standard immunotherapy and bone marrow transplantation has dramatically improved the survival of patients over the years. The optimum immunotherapy with antithymocyte globulin and cyclosporine has been developed and patients who failed even to second course of immunotherapy were also subjected to bone marrow transplantation. These strategies have achieved and improved the event free but significant numbers of cases were refractory to these treatments.

Initial studies of thrombopoietin-MPL system revealed their activity to increase the number of committed progenitor cells along with their proliferation in all three lineages. Peptide agonists such as eltrombopag can bind to MPL region to initiate lineage responses. Initially it was shown to induce significant stimulus to increase platelets in patients of chronic idiopathic thrombocytopenic purpura. Subsequent clinical trials have revealed that eltrombopag induced erythropoietic stimulus even in patients of refractory aplastic anemia and resulted in improved event free and overall survivals. In the present manuscript the role of eltrombopag along with standard immunotherapy has been briefly reviewed in aplastic anemia.

ABBREVIATIONS

SAA: Severe Aplastic Anemia; HLA: Human Leukocyte Antigen; ATG: Antithymocyte Globulin; HSC: Hematopoietic Stem Cells; TPO: Thrombopoietin; FDA: Food and Drug Administration

INTRODUCTION

Aplastic anemia is characterized by severe deficiency of red cells, white cells & platelets. This pancytopenia is the result of hypo cellular bone marrow without any evidence of abnormal cellular infiltration or presence of marrow fibrosis [1]. Aplastic anemia can be mild, moderate or severe based upon the severity of aplastic anemia and natural course of the disease. Severe aplastic anemia (SAA) has been defined with bone marrow cellularity of less 25% or cellularity between 25-50% with residual hematopoietic cells of less than 30% along with two of three parameters (a) absolute neutrophil count <0.5 x 10^9/L (b) reticulocyte count <20 x 10^9/L and (c) platelet count <20 x 10^9/L. These changes are secondary to marked reduction in hematopoietic stem cells and lineage committed progenitor cells in the bone marrow. Aplastic anemia is generally an acquired disorder and prevalence of familial disease is rare. In majority of acquired aplastic anemia the etiology of aplastic anemia can’t be identified. It is believed that cytotoxic T-lymphocytes by immune mechanism interact with hematopoietic stem & progenitor cells resulting in their destruction leading to low number of CD34 cells & specific subpopulation of various progenitor cells. Recently it has been observed that short telomeres of white cells at presentation is associated with higher risk of relapse and chromosomal instability can be detected in bone marrow cells of patients much earlier before the evolution of aplastic anemia to myelodysplastic syndrome or leukemia [2,3]. It is essential to exclude inherited disorders of bone marrow failure syndromes such as Fanconi’s anemia, Schwachman-Diamond syndrome, Dyskeratosis congenita by appropriate tests before establishing the diagnosis of acquired aplastic anemia.

BONE MARROW TRANSPLANTATION

Younger patients (<45 years) with SAA, who have human leukocyte antigen(HLA) matched sibling donor have the best option of treatment by allogeneic bone marrow transplantation which offers complete cure in 90% of individuals [1,4,5]. It is unfortunate that matched healthy siblings donors are available in nearly 30% of cases. While results of allogeneic bone marrow transplantation from matched unrelated donors are poor. Improvement in conditioning regimens in future may result in improving the cure rates.

CURRENT IMMUNOSUPPRESSIVE THERAPY

Several retrospective studies along with randomized studies have demonstrated that horse antithymocyte globulin (ATG)
Eltrombopag is only TPO non-peptide molecule that has been developed which has high affinity to bind with MPL. Romiplostim is also approved TPO peptide mimic. These are genetically engineered to bind with high affinity to stimulate MPL. Eltrombopag binds with MPL to activate JAK / STAT and MAPK pathways [19]. Its binding site on MPL is different from that of TPO. Therefore TPO & eltrombopag have additive effects. It is rapidly absorbed after oral administration & its peak levels are achieved within 2-6 hours [20]. It should be taken on empty stomach for its better absorption. It is metabolized in the liver by cytochrome 450 system. Clearance of eltrombopag is 33-52% lower in Asian people & therefore its dose recommended for Asians is half as compared with other ethnic people [21]. Based upon various phase III clinical trials it has been approved for use in patients with chronic immune thrombocytopenia purpura [21-24], and for management of thrombocytopenia in patients with chronic liver disease secondary to hepatitis C infection [25-27].

**ELTROMBOPAG IN SAA**

Eltrombopag being a small molecule & therefore it enters the bone marrow niche more effectively than endogenous TPO [28]. It being oral drug & thus it can be administered easily for prolonged periods. Initially phase II study was conducted at National Institute of Health (NIH) in USA where 25 cases of SAA who had failed to respond to one or more courses of ATG were included to evaluate its efficacy over 12 weeks study period. Its starting dose was 50mg/day which was escalated every 15 days until a maximum dose of 150mg/day [29]. Eleven of 25 (44%) patients achieved the primary response at least in one lineage at 12 weeks (9 patients had platelet response and 2 patients each had neutrophil and hemoglobin response). Seven of these patients continued to receive eltrombopag (150mg/day) for 8-32 (median 16) months. Bone marrow examination revealed normalization of hematopoiesis in all three cell lines without any increase in myelofibrosis. This was first landmark study which demonstrated that eltrombopag induced multilineage response in SAA. Subsequently 18 more patients were included in the above study which revealed that 17 of 43 (40%) patients had either bilineage or trilineage response at 3-4 months [30]. An important observation in the study was that patients having unilineage or bilineage response at 12 weeks on continuation of eltrombopag therapy had trilineage response. Seventeen patients had normalization of blood counts & five of them discontinued eltrombopag after a median of 28.5 (9-37) months. All these patients were in remission with a median follow up of 13 (1-15) months [30]. Gill & their colleagues in their review [31], reported retrospective analysis of 10 patients with AA/ SAA who were treated with eltrombopag had overall response rate of 70% and 30% of these patients had trilineage response. They further observed that responses were dose dependent and a dose of 450 mg/day (white patients equivalent) had no significant toxicities on prolonged administration. In another phase II study 88 newly diagnosed cases of SAA who were undergoing ATG and cyclosporine therapy were also given eltrombopag [32]. In this study patients were divided in 3 cohorts, cohort 1 (n=30) patients received eltrombopag from 3rd week to 6 months, in cohort 2 (n=31) eltrombopag was given from 3rd week to 3 months while in cohort 3 (n=27) it was given from day 1 to 6 months with primary endpoint of complete response at 6 months. Overall and...
complete responses were seen in 80% & 30% in cohort 1, 87% & 36% in cohort 2 and in 92% & 54 % in cohort 3 patients. Patients who responded, the median time to become independent of red cell transfusion was 42 days & 32 days for platelets. In this study 12 patients underwent hematopoietic stem cell transplantation for relapse in 3 cases, evolution to myelodysplastic syndrome in 3 and refractoriness to therapy in 6 cases. These results are much superior to patients receiving standard immunotherapy [31]. Among three cohorts in the study overall complete responses were superior in patients of cohort 3. Transaminitis was frequent adverse effect which was reversible with short interruption of therapy without needing any dose reduction [28,30]. While gastrointestinal adverse effects (dyspepsia, abdominal pain etc) can be controlled without reducing the dose by symptomatic therapy. Eltrombopag therapy in SAA has resulted in cytogenetic abnormalities including partial deletion, loss of chromosome 7, [30], and monosomy 7 [31].

Over all these studies indicate that eltrombopag along with standard immunotherapy is able to increase the HSC number and also increases the proliferation of stem cells in the bone marrow (Figure 1). It is quite dear from all these studies that addition of eltrombopag to standard immunotherapy with ATG & cyclosporine combination is very promising. However large multicentric studies over prolonged periods are essential to determine the efficacy, optimal dose and duration of eltrombopag therapy in patients of SAA. Long term follow up studies after stopping eltrombopag will reveal complete cure rates or evolution of SAA to other stem cell disorders. If these studies confirm the present results then standard immunotherapy along with eltrombopag may even replace the bone marrow transplantation in SAA.

CONFLICT OF INTEREST

It is to certify that the author has no financial interest in preparation of this brief review. There is no conflict of interest with the studies cited while reviewing the literature on the subject.

REFERENCES


Cite this article


